Compare KE Holdings Inc (BEKE) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KE Holdings Inc vs BioNano Genomics Inc — how do they compare? KE Holdings Inc trades at $17.36 (market cap $18.92B), while BioNano Genomics Inc trades at $1.2 (market cap $13.66M). The key difference: KE Holdings Inc is far larger — about 1385.1× BioNano Genomics Inc's market cap, and KE Holdings Inc pays a 1.63% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BEKE | BNGO | |
|---|---|---|
Market Cap | $18.92B | $13.66M |
Sector | Technology | Health |
52-Week High | $20.36 | $4.92 |
52-Week Low | $14.26 | $1.06 |
Enterprise Value | $14.66B | $16.26M |
Dividend Yield | 1.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BEKE trades at $17.335, down 1.78% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent Q1 2026 earnings beat expectations with EPS of $0.20 versus $0.14, driven by cost controls and operational efficiency. Revenue for 2025 was $94.58 billion, with a net income margin of 3.76%, though cash flow from operations was negative $376.17 million.
The outlook is positive given analyst support and potential trend reversal from oversold conditions, but risks include reliance on China's property market and volatile cash flows. The stock presents a growth opportunity if operational improvements continue, yet investors face exposure to macroeconomic and regulatory headwinds in the housing sector.
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KE Holdings Inc
KE Holdings (Beike) is China’s leading platform for housing transactions and services. It operates the Lianjia brand and uses data-driven technology to facilitate home sales, rentals, and home renovation services.
Read more on BEKE →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
